AbbVie wins expanded European approval for Venclyxto in first-line leukemia

AbbVie (NYSE:ABBV) has secured authorization from the European Commission for an expanded label of its oncology drug VENCLYXTO (venetoclax) to treat adult patients with previously untreated chronic lymphocytic leukemia (CLL).

The regulatory approval introduces new all-oral, fixed-duration treatment combinations to the first-line setting.

Under the expanded indication, Venclyxto can now be prescribed in combination with acalabrutinib, with or without obinutuzumab, as well as in a separate combination regimen with ibrutinib.

The decision expands the therapeutic options available to physicians, allowing for entirely chemotherapy-free and time-limited treatment paths for patients managing the bone marrow and blood cancer.

The European Commission’s decision is backed by robust data from multiple clinical trials, including the Phase 3 AMPLIFY and GLOW studies, alongside findings from the Phase 2 CAPTIVATE study.

Data from these trials demonstrated that the newly authorized fixed-duration regimens allow patients to achieve deep clinical responses, subsequently granting them extended treatment-free intervals where active therapy can be safely paused.

The geographical scope of the authorization applies uniformly across all European Union member states, additionally extending to Iceland, Norway, and Liechtenstein.

The regulatory milestone strengthens AbbVie’s position within the global oncology market and provides a broader clinical framework for treating CLL in the European region without reliance on traditional chemotherapy regimens.